Panitumumab-IRDye800CW (Stanford University)

Generic Name: Panitumumab-IRDye800CW (Stanford University)

Clinical Trials

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients with Head and Neck Cancer

Phase 1

Recruiting

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Panitumumab-IRDye800
Other: Indium In 111 Panitumumab
Procedure: Single Photon Emission Computed Tomography
Procedure: Computed Tomography
Procedure: Resection
Procedure: Fluorescence Imaging

First Posted Date: 2023-07-14

Last Posted Date: 2024-12-13

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 40

Registration Number: NCT05945875

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Phase II Panitumumab-IRDye800 in Head & Neck Cancer

Phase 2

Recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Panitumumab-IRDye800

First Posted Date: 2020-08-12

Last Posted Date: 2025-04-16

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 25

Registration Number: NCT04511078

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures

Phase 1

Not yet recruiting

Conditions: Brain Tumor

Interventions: Drug: Panitumumab-IRDye800
Device: Pinpoint-IR9000 endoscopic/handheld device
Device: Explorer Air camera
Device: PDE-NEO-II

First Posted Date: 2019-09-11

Last Posted Date: 2024-12-27

Lead Sponsor: Stanford University

Target Recruit Count: 12

Registration Number: NCT04085887

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States

Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck
Carcinoma of the Head and Neck

Interventions: Drug: Panitumumab-IRDye800
Drug: 89-Zirconium (Zr-89) Panitumumab
Device: Pinpoint IR IR9000 fluorescence imaging system (FIS)
Device: SPY-PHI IR9000 fluorescence imaging system (FIS)
Device: Explorer Air camera
Device: PDE-NEO II camera
Device: FIS-00 fluorescence imaging system (FIS)
Device: Da Vinci Firefly Imaging System
Device: IGP-ELVIS-v4 Macroscopic Specimen Imager
Device: Vevo 3100 LAZR-X
Device: Pearl Triology Imaging System
Device: Odyssey CLx Imaging System
Device: Leica fluorescence microscope

First Posted Date: 2018-11-07

Last Posted Date: 2023-05-19

Lead Sponsor: Andrei Iagaru

Target Recruit Count: 14

Registration Number: NCT03733210

Locations: 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Phase 1

Recruiting

Conditions: Lung Carcinoma
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Metastatic Malignant Neoplasm in the Lung
Stage IV Lung Cancer AJCC v8

Interventions: Procedure: Near-Infrared Fluorescence Imaging
Drug: Panitumumab-IRDye800
Other: Pharmacokinetic Study
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2018-07-10

Last Posted Date: 2025-02-19

Lead Sponsor: Eben Rosenthal

Target Recruit Count: 30

Registration Number: NCT03582124

Locations: 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Phase 1

Recruiting

Conditions: Malignant Brain Neoplasm
Malignant Glioma

Interventions: Procedure: Near-Infrared Fluorescence Imaging
Biological: Panitumumab
Drug: Panitumumab-IRDye800
Device: POINPOINT-IR9000

First Posted Date: 2018-04-27

Last Posted Date: 2025-02-12

Lead Sponsor: Eben Rosenthal

Target Recruit Count: 46

Registration Number: NCT03510208

Locations: 🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Head and Neck Cancer

Interventions: Drug: Panitumumab-IRDye800
Drug: Lymphoseek

First Posted Date: 2018-01-19

Last Posted Date: 2022-11-10

Lead Sponsor: Eben Rosenthal

Target Recruit Count: 3

Registration Number: NCT03405142

Locations: 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Phase 1

Recruiting

Conditions: Pancreatic Adenocarcinoma

Interventions: Procedure: Fluorescence Imaging
Biological: Panitumumab
Drug: Panitumumab-IRDye800

First Posted Date: 2017-12-27

Last Posted Date: 2025-02-17

Lead Sponsor: Eben Rosenthal

Target Recruit Count: 27

Registration Number: NCT03384238

Locations: 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy